Editorial  by unknown
Editorial Comment




PETER C. BLOCK, MD
Portland, Oregon
In this issue the Hirulog angioplasty study investigators (1)
report patients who had transient closure of the target vessel
during percutaneous transluminal coronary angioplasty for
unstable angina. The vessel was reopened and patients had a
“successful” procedure without in-hospital death, urgent by-
pass surgery or clinical evidence of myocardial infarction. The
study’s aim was to identify predictors of adverse cardiac events
after successful coronary angioplasty. Their findings are no
surprise—univariable predictors of adverse events include
emergency stenting, multilesion angioplasty, diabetes, target
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lesion in the left anterior descending artery and smaller final
lumen diameter. But, in a multivariable model, abrupt vessel
closure was the strongest independent predictor of major
adverse cardiac events (MACE) at 6 months (death, myocar-
dial infarction, or repeat vascularization). Multivessel angio-
plasty, target lesion in the left anterior descending artery and
diabetes also remain independent predictors. The authors
conclude that “uncomplicated” abrupt vessel closure that is
corrected during angioplasty can result in a “successful” pro-
cedure, but predicts worse eventual outcome.
Before discussing some of the implications of these findings,
it would be remiss not to point out factors in this report that
were not predictive of MACE at 6 months. Perhaps most
controversial is the finding that asymptomatic elevation of
creatine kinase (CK) was not predictive. Measurements of CK
were performed 8 and 16 h after angioplasty, and 99% of
patients in the trial had at least one CK measurement per-
formed—indicating that this finding likely has validity. Though
the jury is still out on what asymptomatic CK elevations after
angioplasty mean, their data support the notion that this may
not be as important as other variables. This is in contrast to
previous findings that even minor elevations of CK after
coronary interventions may predict reduced event-free sur-
vival. We are not told about ejection fractions in the patients
included in the study and the effect of CK elevations on
ejection fraction after the procedure. This may account for
some of the differences.
Also surprising is that lesion length, reference diameter,
final percent stenosis, residual stenosis of greater than 50%
and persistent dissection at completion of the procedure were
not statistically associated with increased MACE at follow-up.
However, patients with abrupt closure had significantly more
complex lesions than patients without closure; less often type A
(24% vs. 37%; p 5 0.001); less often discrete (74% vs. 81%;
p 5 0.01); higher prevalence of filling defects (5% vs. 2%; p 5
0.01); features suggesting thrombus (21% vs. 13%; p 5 0.001),
and more severe stenosis at the target site (74 6 15% vs. 71 6
16%; p 5 0.001). Though the definition of “successful” angio-
plasty was a loose one—performed without a major in-hospital
ischemic complication—it is reasonable to believe that the
operators in this trial established Thrombolysis in Myocardial
Infarction trial (TIMI) 3 flow in the target vessel before
completion of the procedure. In the trial less than TIMI 3 flow
was defined as “threatened closure” and was therefore treated.
Though established in thrombolytic trials, TIMI 3 flow in a
target vessel may be as important as the anatomic features seen
angiographically at the time of angioplasty. This raises the
question of why transient abrupt vessel closure is “bad” in the
long term. Perhaps vessel closure is a surrogate for complex
adverse morphologic and procedural characteristics that we
cannot easily measure by conventional means. A more intrigu-
ing answer is that vessel closure—and reopening—alters the
physiology of the lesion, leading to a poorer long-term out-
come. If so, platelet interactions with the briefly occluded
vessel may be the culprit.
A problem with the report by Piana et al. (1) is that the
Hirulog study represents a “snapshot” of a moving target. The
patients were recruited in 1993 and early 1994. Use of glyco-
protein IIb/IIIa inhibitors in coronary interventions was un-
common at that time, and their effect on the Hirulog study
patient population with unstable angina was not studied.
Would their use have made long-term outcome better? The
randomized trials provided some mixed clues. The EPIC (2)
and EPILOGUE (3) studies showed that outcome is improved
during routine angioplasty in patients treated with abciximab,
so we could conclude that treatment with a IIb/IIIa inhibitor
might have affected the outcome even with transient occlusion.
In EPIC there was a 35% event reduction in the abciximab
bolus plus infusion treatment group versus placebo (p 5
0.008). The reduction was mostly due to the rate of nonfatal
myocardial infarction and need for emergency angioplasty
and/or coronary artery bypass grafting (at the risk of major
bleeding and need for transfusion). Benefit, however, seems to
be present for as long as 3 years in the abciximab-treated
group. In EPILOGUE the 6-month end point of death,
myocardial infarction or any intervention was decreased by
12% in the abciximab plus heparin group compared to placebo
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and heparin (p 5 0.03). In CAPTURE (4), however, despite a
20% risk reduction by abciximab at 30 days (p 5 0.01) there
was no difference for the composite end point at 6 months.
Meta-analysis of stented patients (5) from EPIC, EPILOGUE
and CAPTURE showed a reduction in MACE from 30% to
22.4% (p 5 0.026). The shorter acting IIb/IIIa antagonists
(tirofiban, eptifibatide) also show significant early short-term
effects. In patients receiving tirofiban alone (PRISM [6]),
tirofiban and heparin (PRISM-PLUS [7], RESTORE [8]),
eptifibatide and heparin (PURSUIT [9], IMPACT II [10]),
composite end points were uniformly improved in the treat-
ment group (except for the tirofiban alone group in PRISM-
PLUS). Six-month composite end point benefits have also been
demonstrated for tirofiban plus heparin in PRISM-PLUS (11).
With oral IIb/IIIa inhibitors “on the way” the strategy for
treating transient vessel closure during angioplasty might be-
come giving patients a short-acting agent during hospitaliza-
tion and continuing oral IIb/IIIa inhibitor therapy for long-
term benefit. Most operators today would routinely use IIb/
IIIa inhibitors after angioplasty for patients in whom transient
closure occurred. Whether this strategy is correct may soon be
known.
Another issue under scrutiny in coronary interventions is
whether or not a “near perfect” angioplasty is equivalent to
elective stent placement. Several studies have supported this
concept (DEBATE [12], BENESTENT II subgroup [13],
EPILOGUE subgroup [3], REST [14], OCBAS [15]). The
lower cost of angioplasty versus stenting with or without the
use of additional therapies may bring us to the conclusion that
we should not stent as frequently as we do today. However, if
universal attempts to produce a “near perfect” angioplasty
with a residual lumen of less than 20% (occasioned by the use
of oversized balloons, higher pressures, etc.) result in a higher
rate of vessel disruption and threatened closure, long-term
negative effects may not be worth the short-term lesser cost.
Revascularization was necessary in 21% of patients in the
Hirulog study, and MACE occurred in more than 1/5 of
patients—a significant number of these predicted by transient
vessel closure. Will the attempts to make an angioplasty as
close to perfect as possible result in a higher number of
threatened or abrupt closures that need to be dealt with in the
laboratory? The CLOUT (16) trial showed that balloon choice
compared to intravascular ultrasound interrogation of the
target vessel was frequently (73%) undersized (average bal-
loon:artery ratio of 1.3:1). Subsequent angioplasty with larger
balloons did not increase angiographic dissection, but it is
unlikely that this strategy will be widely used.
In the early days of angioplasty abrupt vessel closure was
indeed an ill wind. It was the reason for “surgical standby” and
occurred in the hours after the procedure as well as during the
procedure itself. Times have changed. Not only is vessel
closure now less frequent—almost certainly due to better
hardware, a wider array of interventional tools and greater
experience—but if vessel closure occurs it is usually possible to
reestablish flow resulting in a “successful” procedure. The use
of perfusion balloons, stenting, IIb/IIIa inhibitors and an
assortment of elegant angioplasty tools has resulted in only a
small percentage of patients needing urgent surgical revascu-
larization.
Despite the changes in practice that have occurred since the
Hirulog study was initiated, we should not throw the baby out
with the bathwater. Exact prediction of abrupt vessel closure
remains impossible. Everyone would agree that techniques to
reduce vessel closure would be helpful. But the lesson from this
study is that patients who experience abrupt vessel closure
during angioplasty and end up with a “successful” procedure
still have a higher rate of MACE later on. The ill wind of
transient vessel closure is still blowing. Though it produces
fewer acute problems, patients touched by it seem to experi-
ence a higher incidence of adverse events in the long term, and
we need to discover what can be done to change the outcome.
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